ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Holland On The Next 10 Years; Progress In Prevention, Diagnosis, Therapy

March 23, 1984

Phase III PANORAMA-1 Trial Meets PFS Primary Endpoint

June 27, 2014

Patients on Hypertension Meds Lived Longer, Analysis Shows

January 31, 2014

In Brief: Lepovetsky Heads New NCI Office Of Technology Development; Temporary Now, Maybe Permanent

November 27, 1987

NIH Open “One-Stop Shop” For Mutant Mouse Models.

July 20, 2001

DCT Board Approves Lung Cancer Drug Discovery Project, First Targeted Anticancer Agent Search

June 22, 1984